Construct Validity of the Impact of Weight on Quality of Life Questionnaire

Kolotkin, Ronette L.; Head, Susan; Brookhart, Alan

doi:10.1002/j.1550-8528.1997.tb00667.x

Cited by 83 publications

(60 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The drop-out rate (16% in the treatment group and 11% in the control group) in our study was small compared to many other weight loss studies. 14,19,22,25,38 Therefore, despite the small sample size, the effects were similar in the completer and ITT populations, further validating our results. However, there are limitations to this study.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Health-related quality of life in WHO Class II–III obese men losing weight with very-low-energy diet and behaviour modification: a randomised clinical trial

et al. 2002

View full text Add to dashboard Cite

Objective: To study health-related quality of life responses to marked weight loss in WHO Class II -III (body mass index (BMI) ! 35 kg=m 2 ) obese men. Design: An 8 month randomised clinical trial with a 4 month weight loss programme (10 weeks on a very-low-energy diet (VLED) and 17 behaviour modification visits) in the treatment group and no intervention in the control group. Subjects: Nineteen men (mean age 45.9 y, mean BMI 39.3 kg=m 2 ) in the treatment group and 19 men (47.2 y, 39.4 kg=m 2 ) in the control group. Measurements: Weight and questionnaires measuring health-related quality of life (RAND 36-Item Health Survey 1.0 and obesity-related psychosocial problems scale). Results: In the treatment group, the mean (s.d.) weight loss was 17.0 (7.4)% at the end of the 4 month therapy. At the end of follow-up, nearly 6 months after the end of VLED in the treatment group, the average maintained weight loss was 13.9 (7.8)% of baseline weight. The control group was weight stable throughout the study. During treatment, there was only transient improvement in general health, bodily pain, mental health, emotional role functioning and vitality (all increases in the scores were not statistically significant). Improvements in physical functioning, social functioning and obesity-related psychosocial problems were maintained until the end of follow-up. The treatment group also reported improvement in perceived health in the past year. There was only minor fluctuation in questionnaire scores in the control group. Conclusion: The short-term and maintained health-related quality of life effects of weight loss may differ. Marked weight loss in WHO Class II -III obese men leads to improvements in physical functioning, social functioning, obesity-related psychosocial problems, and perceived health; these improvements were maintained at 4 month post-intervention follow-up.

show abstract

Section: Discussionsupporting

confidence: 84%

“…A few obesity-specific quality of life questionnaires addressing psychosocial functioning have been developed, 3,14,17 although no randomised intervention trials have previously been published. Again, the strongest evidence available regarding the effects of weight loss has been produced among surgically treated morbidly obese patients.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life in WHO Class II–III obese men losing weight with very-low-energy diet and behaviour modification: a randomised clinical trial

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The IWQOL-Lite is a 31-item version of its parent instrument, the Impact of Weight on Quality of Life (IWQOL) questionnaire [63,64]. Data collected from 996 obese patients and controls were used to develop the shorter measure [61].…”

Section: Impact Of Weight On Quality Of Life (Iwqol)-litementioning

confidence: 99%

Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery

et al. 2004

View full text Add to dashboard Cite

Background: Measuring health-related quality of life (QoL) after surgery is essential for decision making by patients, surgeons, and payers. The aim of this consensus conference was twofold. First, it was to determine for which diseases endoscopic surgery results in better postoperative QoL than open surgery. Second, it was to recommend QoL instruments for clinical research. Methods: An expert panel selected 12 conditions in which QoL and endoscopic surgery are important. For each condition, studies comparing endoscopic and open surgery in terms of QoL were identified. The expert panel reached consensus on the relative benefits of endoscopic surgery and recommended generic and disease-specific QoL instruments for use in clinical research. Results: Randomized trials indicate that QoL improves earlier after endoscopic than open surgery for gastroesophageal reflux disease (GERD), cholecystolithiasis, colorectal cancer, inguinal hernia, obesity (gastric bypass), and uterine disorders that require hysterectomy. For spleen, prostate, malignant kidney, benign colorectal, and benign non-GERD esophageal diseases, evidence from nonrandomized trials supports the use of laparoscopic surgery. However, many studies failed to collect long-term results, used nonvalidated questionnaires, or measured QoL components only incompletely.

show abstract

“…[1][2][3] Weight loss achieved by surgical techniques 1 and lifestyle interventions [4][5][6][7][8][9][10][11] has improved HRQL. Diabetes with its complications has been associated with deteriorated HRQL [12][13][14][15][16] and improvement in glycaemic control with the loss of hyperglycaemic symptoms has improved HRQL in type II diabetes patients.…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

2004

View full text Add to dashboard Cite

OBJECTIVE:We evaluated the effects of 12-month treatment with sibutramine 15 mg daily compared with placebo on healthrelated quality of life (HRQL) in obese type II diabetes patients. We examined the associations between the changes in HRQL and in weight, glycaemic control, and haemodynamic variables. We also explored the predictive value of HRQL and its changes early during treatment. DESIGN: A randomised clinical trial. The subjects were enrolled in a 2-week single-blind run-in period with a modestly hypocaloric diet (700 kcal daily deficit) and then randomised to receive either sibutramine 15 mg (n ¼ 114, 60% female) or placebo (n ¼ 122, 58% female) once daily with the hypocaloric diet for 12 months. SUBJECTS: Obese (mean BMI 36 kg/m 2 and age 54 y) type II diabetes patients untreated with antidiabetic medications. MEASUREMENTS: The main outcome measures included body weight and HRQL (the RAND 36-Item Health Survey 1.0). RESULTS: The mean weight loss was greater in the sibutramine group (À7.1 kg) than in the placebo group (À2.6 kg, Po0.001). The baseline HRQL was relatively high. There were no significant differences between the treatment groups in glycaemic control or in any of the RAND-36 scales during the study. The scores on physical functioning (PF) and health change (HC) since last year improved in both groups and this improvement was related to weight loss. When HRQL changes were examined in categories of weight loss, the scores on PF and HC increased with Z5% weight loss, but the scores on vitality (V) and general health (GH) increased only after Z15% weight loss. Decrease in HbA1c was associated with increases in the scores of PF, GH, V, mental health, and HC. In the sibutramine group, the increase in diastolic blood pressure was associated with the decrease in the scores of PF, physical role functioning, emotional role functioning (ERF), social functioning (SF), and bodily pain. High baseline scores on ERF and SF, and low scores on V predicted weight loss at 12 months. Also, increasing scores on PF and V during the first 3 months predicted weight loss at 12 months. The sum of four dichotomised HRQL variables (baseline ERF Z75 ¼ 1 and o75 ¼ 0; baseline SFZ80 ¼ 1 and o80 ¼ 0; 3-month change in PF40 ¼ 1 and r0 ¼ 0; 3-month change in V40 ¼ 1 and r0 ¼ 0) predicted weight loss: In the group with sum 0, the mean(s.d.) weight change at 12 months was 0.0(2.6)% and with sum 4 it was -9.0(8.1)% of baseline weight. CONCLUSION: Despite the superior weight loss, sibutramine 15 mg daily did not produce HRQL benefits over placebo when measured with the generic RAND-36 in obese type II diabetes patients. PF and HC since last year improved with Z5% weight loss, but Z15% weight loss was needed to achieve a cluster of HRQL improvements. The decrease in HbA1c was associated with many HRQL benefits. Poor baseline HRQL and the improvement observed in the first months of treatment may prove to be useful in predicting success in long-term weight loss.

show abstract

Construct Validity of the Impact of Weight on Quality of Life Questionnaire

Cited by 83 publications

References 17 publications

Health-related quality of life in WHO Class II–III obese men losing weight with very-low-energy diet and behaviour modification: a randomised clinical trial

Health-related quality of life in WHO Class II–III obese men losing weight with very-low-energy diet and behaviour modification: a randomised clinical trial

Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

Contact Info

Product

Resources

About